INVENTIVA SA - ADR
IVANASDAQTrading Snapshot
- Day Range
- $3.65 – $3.74
- 52-Week Range
- $3.11 – $7.98
- Volume
- $2.28B
- Avg Volume
- $2.27B
- Shares Outstanding
- 52.0M
- Next Earnings
- Nov 29, 2026
Fundamentals Snapshot
- Annual Revenue
- $4M
- Last Q Revenue
- $20,268
- P/E Ratio
- -6.1
- P/S Ratio
- 15595.4x
- EPS (TTM)
- $-0.91
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +1125.6%
Why Investors Own IVA
- ✓High-growth profile — revenue up +14.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 31% gross margin and 6% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
INVENTIVA SA - ADR
IVA
StockOtter · stockotter.spaceAbout INVENTIVA SA - ADR
Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics. The firm primarily targets serious conditions such as non-alcoholic steatohepatitis (NASH), various forms of mucopolysaccharidoses (MPS), and other significant diseases. The company's most advanced experimental drug is Lanifibranor, which has successfully completed Phase IIb clinical trials for the treatment of NASH. Inventiva is also progressing with Odiparcil, an asset that has finished its Phase IIa clinical studies for addressing the MPS VI subtype disease. Beyond these lead candidates, Inventiva maintains a robust pipeline of earlier-stage research and development programs, notably in oncology and other therapeutic areas. The company has also established important strategic alliances, including a partnership with AbbVie focused on treatments for autoimmune diseases, and a collaboration with Boehringer Ingelheim International GmbH aimed at discovering novel therapies for idiopathic pulmonary fibrosis. Inventiva S.A. was established in 2011 and is headquartered in Daix, France.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Inventiva (NASDAQ:IVA) Stock Price Up 5.5% – Time to Buy?
Inventiva S.A. Sponsored ADR (NASDAQ: IVA - Get Free Report) shares rose 5.5% on Monday. The stock traded as high as $3.56 and last traded at $3.5540. Approximately 1,594,845 shares traded hands during mid-day trading, a
Vail Resorts, Inventiva And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Tuesday.
Inventiva S.A. (IVA) Q2 2026 Earnings Call Transcript
Inventiva S.A. (IVA) Q2 2026 Earnings Call Transcript
Inventiva Q2 Earnings Call Highlights
Inventiva NASDAQ: IVA said it remains on track to report top-line results from its Phase III NATiV3 trial of lanifibranor in metabolic dysfunction-associated steatohepatitis, or MASH, in the fourth quarter of 2026, after
Inventiva Reports Unaudited 2026 First-Half Financial Results and Provides Corporate Update
Daix (France), New York (New York, United States), September 28, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of
Inventiva S.A. (IVA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Inventiva S.A. (IVA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript